Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis.
- DOI
- 10.1038/bjc.2017.67
- Published
- 2017-03-28
- Container
- Br J Cancer
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1038/bjc.2017.67,
title = {Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis.},
author = {Pelzer U and Blanc JF and Melisi D and Cubillo A and Von Hoff DD and Wang-Gillam A and Chen LT and Siveke JT and Wan Y and Solem CT and Botteman MF and Yang Y and de Jong FA and Hubner RA.},
year = {2017},
journal = {Br J Cancer},
doi = {10.1038/bjc.2017.67},
url = {https://doi.org/10.1038/bjc.2017.67}
}RIS
TY - JOUR TI - Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis. AU - Pelzer U AU - Blanc JF AU - Melisi D AU - Cubillo A AU - Von Hoff DD AU - Wang-Gillam A AU - Chen LT AU - Siveke JT AU - Wan Y AU - Solem CT AU - Botteman MF AU - Yang Y AU - de Jong FA AU - Hubner RA. PY - 2017 JO - Br J Cancer DO - 10.1038/bjc.2017.67 UR - https://doi.org/10.1038/bjc.2017.67 ER -
APA
U, P., JF, B., D, M., A, C., DD, V. H., A, W., LT, C., JT, S., Y, W., CT, S., MF, B., Y, Y., FA, D. J., & RA., H. (2017). Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis.. Br J Cancer. https://doi.org/10.1038/bjc.2017.67
Source records
- europe-pmc · retrieved 2026-09-27T05:21:52.691Z